公开(公告)号：US20050084493A1

公开(公告)日：2005-04-21

申请号：US10985299

申请日：2004-11-09

Applicant: Alison Witte ,  Brian Varnum ,  Xueming Qian ,  Chris Vezina

Inventor： Alison Witte ,  Brian Varnum ,  Xueming Qian ,  Chris Vezina

IPC: C07K16/24 ,  A61K39/395

CPC classification number: C07K16/245 ,  A61K2039/505 ,  C07K2317/24

Abstract: The invention concerns methods of treating IL-1-mediated disease by administering a selective IL-1 binding agents that form an antagonist complex with the IL-1 ligand. The antagonist complex can bind to the IL-1 receptor without activating the receptor. The selective binding agents contemplated by this invention thus have the properties of free ligand absorption (through binding of the selective binding agent to free IL-1α or β) and receptor activation inhibition (through binding of the antagonist complex to the receptor and preventing its activation).

Abstract translation: 本发明涉及通过施用与IL-1配体形成拮抗剂复合物的选择性IL-1结合剂来治疗IL-1介导的疾病的方法。 拮抗剂复合物可以结合IL-1受体而不活化受体。 因此，本发明考虑的选择性结合剂具有游离配体吸收（通过结合选择性结合剂与游离IL-1α或β）和受体活化抑制（通过拮抗剂复合物与受体结合并防止其活化）的性质 ）。